Latest News on PRTA

Financial News Based On Company


Advertisement
Advertisement

Prothena Corp PLC (0PT.SG) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/0PT.SG/seasonality/
The article provides a seasonal returns chart for Prothena Corp PLC (0PT.SG) on Yahoo Finance. It displays the average monthly price return for the period between 2016 and 2026. The stock is currently trading at 7.13 EUR, down 1.05%.

Prothena Corp PLC (0PT.SG) Seasonal returns chart

https://uk.finance.yahoo.com/quote/0PT.SG/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for Prothena Corp PLC (0PT.SG). It shows the average monthly price return for the stock between 2016 and 2026. The article also includes current stock data and links to other financial information for Prothena.

Form 4 PROTHENA CORP PUBLIC LTD CO: William P. Scully (10% Owner) For: 6 November

https://uk.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-william-p-scully-10-owner-for-6-november-93CH-4972700
This article reports on a Form 4 filing for Prothena Corporation Public Limited Company, indicating that William P. Scully, a 10% owner, made transactions on November 6th. The filing is a standard regulatory disclosure for insider trading. The company's stock symbol is PRTA, which experienced a -2.45% change.

Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

https://www.biospace.com/press-releases/prothena-reports-third-quarter-2026-financial-results-and-business-highlights
Prothena Corporation plc announced its financial results for the third quarter and first nine months of 2026, highlighting significant progress in its clinical development pipeline. The company reported a net loss of $16.5 million for Q3 2026 and a cash position of $272.2 million. Key updates include advancements in Phase 3 trials for prasinezumab in Parkinson's disease and coramitug in ATTR amyloidosis, as well as an expected data readout in 1H 2027 for moponetug in Alzheimer's disease.

Prothena earnings missed by $0.11, revenue fell short of estimates

https://www.investing.com/news/earnings/prothena-earnings-missed-by-011-revenue-fell-short-of-estimates-5006593
Prothena (NASDAQ: PRTA) reported third-quarter EPS of $-0.32, missing analyst estimates by $0.11, and revenue of $620K, falling short of the consensus estimate of $9.59M. The company's stock price closed at $7.89, down -9.93% in the last three months and -25.28% in the last 12 months. InvestingPro rates Prothena's financial health as "good performance."
Advertisement

Understanding Momentum Shifts in (PRTA)

https://news.stocktradersdaily.com/news_release/139/Understanding_Momentum_Shifts_in_PRTA_110326033602_1793694962.html
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA), indicating stable neutral readings in shorter horizons may signal an easing of a long-term weak bias. It highlights a mid-channel oscillation pattern and presents an exceptional 35.7:1 risk-reward short setup. The analysis provides AI-generated institutional trading strategies for long, breakout, and short positions, along with multi-timeframe signal analysis and support/resistance levels.

Prothena Corporation plc (0PT.F) Seasonal returns chart

https://au.finance.yahoo.com/quote/0PT.F/seasonality/
The article provides a seasonal returns chart for Prothena Corporation plc (0PT.F), showing the average monthly price return from 2016 to 2026. It indicates the stock's current performance with a slight increase and notes that the Frankfurt market is open.

Form 4 PROTHENA CORP PUBLIC LTD CO: William P. Scully (10% Owner) For: 27 October

https://ng.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-william-p-scully-10-owner-for-27-october-93CH-2772857
This article reports on a Form 4 filing for Prothena Corp Public Ltd Co, indicating that William P. Scully, a 10% owner, was involved in a transaction on October 27. The brief report highlights the insider trading activity for the company, identified by the stock symbol PRTA.

Prothena Corporation plc (0Y3M.IL) Seasonal returns chart

https://uk.finance.yahoo.com/quote/0Y3M.IL/seasonality/
This article from Yahoo Finance provides a seasonality chart for Prothena Corporation plc (0Y3M.IL), displaying the average monthly price return from 2018 to 2026. The stock closed at 24.63 USD, up 2.89%, on July 23 at 21:00:00 BST.

Form 4 PROTHENA CORP PUBLIC LTD CO: William P. Scully (10% Owner) For: 27 October

https://uk.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-william-p-scully-10-owner-for-27-october-93CH-4947195
This article reports on a Form 4 filing for Prothena Corp Public Ltd Co, indicating that William P. Scully, a 10% owner, made transactions on October 27th. The specific details of the transactions are not provided in the snippet, but the filing highlights insider activity.
Advertisement

Prothena to Report Third Quarter 2026 Financial Results on November 5

http://www.streetinsider.com/Business+Wire/Prothena+to+Report+Third+Quarter+2026+Financial+Results+on+November+5/27257741.html
Prothena Corporation plc (NASDAQ: PRTA) announced it will report its third quarter and first nine months of 2026 financial results on Thursday, November 5, 2026, after the close of U.S. financial markets. The company, a late-stage clinical biotechnology firm, will not be hosting a conference call in conjunction with this release. Prothena focuses on developing therapeutics for neurodegenerative and rare peripheral amyloid diseases.

A 566,444-share gift leaves Prothena (PRTA) owner Scully holding 1,753,444 shares directly.

https://www.stocktitan.net/sec-filings/PRTA/form-4-prothena-corp-public-ltd-co-insider-trading-activity-61e40f3023ad.html
William P. Scully, a ten percent owner of Prothena Corp Public Ltd Co (PRTA), received a bona fide gift of 566,444 ordinary shares on October 27, 2026. Following this transaction, his direct holdings increased to 1,753,444 ordinary shares. Additionally, Scully has indirect holdings of 529,000 shares through his spouse and 187,000 shares through Manatee Equity Fund LLC.

Prothena to Report Third Quarter 2026 Financial Results on November 5

https://www.streetinsider.com/Business+Wire/Prothena+to+Report+Third+Quarter+2026+Financial+Results+on+November+5/27257741.html
Prothena Corporation plc (NASDAQ: PRTA) announced it will report its third quarter and first nine months of 2026 financial results on Thursday, November 5, 2026, after the close of U.S. financial markets. The company, a late-stage clinical biotechnology firm, will not be holding a conference call in conjunction with this release. Prothena focuses on investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases.

Form 4 PROTHENA CORP PUBLIC LTD CO: William P. Scully (10% Owner) For: 22 October

https://ng.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-william-p-scully-10-owner-for-22-october-93CH-2758735
This article reports on a Form 4 filing for Prothena Corp Public Ltd Co, indicating that William P. Scully, a 10% owner, made a transaction on October 22. The brief announcement, published on Investing.com, provides no further details on the nature of the transaction.

A ten-percent owner buys Prothena (PRTA) shares at average prices of $8.1852 and $8.0705.

https://www.stocktitan.net/sec-filings/PRTA/form-4-prothena-corp-public-ltd-co-insider-trading-activity-8a267f907d97.html
William P. Scully, a ten-percent owner of Prothena Corp Public Ltd Co (PRTA), recently reported direct purchases of the company's ordinary shares. Scully bought 100,000 shares on October 22, 2026, at an average price of $8.1852 per share, and an additional 50,000 shares on October 23, 2026, at an average price of $8.0705 per share. These transactions significantly increase his direct holdings in Prothena.
Advertisement

Prothena Corporation plc Estimates – NASDAQ:PRTA

https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-estimates/
This page on TradingView provides financial actuals and estimates for Prothena Corporation plc (NASDAQ: PRTA). It allows users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, as well as compare actual results with average, high, and low estimates. The platform also visualizes financial trends over time for the company.

Prothena Corp. Plc Estimates – DUS:0PT

https://www.tradingview.com/symbols/DUS-0PT/financials-estimates/
This page on TradingView provides financial estimates and actuals for Prothena Corp. Plc (0PT) on the Dusseldorf Stock Exchange. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends. The market for 0PT was closed with no trades at the time of publication.

Prothena stock trades at EUR 7.54 with USD 445 million market value

https://www.ad-hoc-news.de/boerse/news/nebenwerte/prothena-stock-trades-at-eur-7-54-with-usd-445-million-market-value/70372318
Prothena stock is trading at EUR 7.54 with a market value of USD 445 million. The company's Q2 revenue was USD 1.01 million, exceeding consensus, and it held USD 288.0 million in cash with no debt as of the end of June. Insider transactions show significant share purchases by ten-percent owner William Scully in mid-October.

William Scully buys 110,000 shares. Analysts target Prothena stock at USD 24.57

https://www.ad-hoc-news.de/boerse/news/nebenwerte/william-scully-buys-110-000-shares-analysts-target-prothena-stock-at-usd-24-57/70353665
William P. Scully, a 10% owner of Prothena Corporation plc (PRTA), recently purchased a total of 110,000 shares, signaling insider confidence. This comes as analysts maintain a "Moderate Buy" consensus with an average target price of USD 24.57. Despite reporting a net loss of USD 18.58 million in Q2 2026, Prothena exceeded revenue and adjusted earnings expectations, leaving clinical execution and cash use as key factors for future updates.

William Scully buys 110,000 shares. Analysts target Prothena stock at USD 24.57

https://www.ad-hoc-news.de/boerse/news/nebenwerte/william-scully-buys-110-000-shares-analysts-target-prothena-stock-at-usd/70353665
William P. Scully, a 10% owner of Prothena Corporation plc (PRTA), purchased an additional 110,000 shares between October 13-14, 2026, signaling confidence in the biotechnology company. This insider buying occurred as analysts maintained a "Moderate Buy" consensus with an average target price of $24.57 for Prothena stock. Despite exceeding Q2 2026 revenue and adjusted earnings expectations, the company reported a net loss of $18.58 million, highlighting that future investment appeal remains tied to clinical progress and potential partnerships.
Advertisement

Form 4 PROTHENA CORP PUBLIC LTD CO: William P. Scully (10% Owner) For: 13 October

https://uk.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-william-p-scully-10-owner-for-13-october-93CH-4913522
This article reports on a Form 4 filing for Prothena Corp Public Ltd Co, indicating that William P. Scully, a 10% owner, made a transaction on October 13th. The filing was published on October 16, 2026. The article provides no further details on the nature of the transaction.

Form 4 PROTHENA CORP PUBLIC LTD CO: William P. Scully (10% Owner) For: 13 October

https://au.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-william-p-scully-10-owner-for-13-october-93CH-4694100
This article reports a Form 4 filing for Prothena Corp Public Ltd Co, indicating that William P. Scully, identified as a 10% owner, made a transaction on October 13. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by insiders. The article provides no further details beyond the filing's existence and the associated parties.

William Scully buys 90,000 shares in Prothena stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/william-scully-buys-90-000-shares-in-prothena-stock/70329994
William Scully, a major shareholder in Prothena, acquired 90,000 additional shares on October 8, 2026, increasing his direct ownership to 529,000 shares. This transaction followed Prothena's Q2 earnings report where revenue exceeded consensus, and occurred shortly after Chief Development Officer Chad J. Swanson's resignation. The company focuses on investigational therapies for neurodegenerative and rare peripheral amyloid diseases, and its next earnings report is estimated for November 5, 2026.

(PRTA) Risk Channels and Responsive Allocation

https://news.stocktradersdaily.com/news_release/20/PRTA_Risk_Channels_and_Responsive_Allocation_101326062601_1791930361.html
This article provides a detailed AI-driven analysis of Prothena Corporation Plc (NASDAQ: PRTA), highlighting a positive near-term sentiment that may be shifting due to broader weak alignment and a mid-channel oscillation pattern. It presents an exceptional 36.0:1 risk-reward short setup and outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.

Prothena development chief resigns: what it means for Prothena stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/prothena-development-chief-resigns-what-it-means-for-prothena-stock/70309010
Prothena's chief development officer, Chad Swanson, resigned effective October 9, 2026, to lead a partnered program with a strategic partner, maintaining a collaboration link for Prothena. This leadership change comes as Prothena reported Q2 2026 revenue of $1.01 million and a diluted EPS of -$0.36, with the next earnings report scheduled for October 29, 2026. The company, a clinical-stage biotech firm, continues to focus on its development pipeline and clinical milestones despite the executive transition.
Advertisement

Form 4 PROTHENA CORP PUBLIC LTD CO For: 11 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-11-october-93CH-2730546
This article provides a brief announcement regarding the filing of Form 4 for PROTHENA CORP PUBLIC LTD CO on October 11. It includes the stock symbol PRTA and mentions a 2.67% increase. The content primarily serves as a placeholder for the SEC filing information.

Form 4 PROTHENA CORP PUBLIC LTD CO For: 10 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-10-october-93CH-2730070
This article announces the filing of Form 4 for Prothena Corp Public Ltd Co, dated October 10. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's stock by its directors, officers, or principal stockholders. The article is very brief, mainly serving as an alert for this SEC filing.

Form 4 PROTHENA CORP PUBLIC LTD CO For: 10 October

https://in.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-10-october-93CH-5626838
This article announces the filing of Form 4 for Prothena Corp Public Ltd Co on October 10. It includes the stock symbol PRTA and notes a 2.67% increase. The content primarily consists of financial market data and trending stock information.

Form 4 PROTHENA CORP PUBLIC LTD CO For: 10 October By Investing.com

https://au.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-10-october-93CH-4682757
This article announces the filing of Form 4 for Prothena Corp Public Ltd Co on October 10th. It is a brief news item from Investing.com, providing information about insider transactions for the company. The article also includes various market data and other news headlines related to financial markets.

Form 4 PROTHENA CORP PUBLIC LTD CO For: 10 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-10-october-93CH-4874393
This article reports on a Form 4 filing for PROTHENA CORP PUBLIC LTD CO (PRTA) on October 10. The filing, dated October 10, 2026, details insider transaction information for the company. PROTHENA CORP PUBLIC LTD CO's stock saw a 2.67% increase at the time of publication.
Advertisement

Prothena stock falls 2.11 percent as development chief exits

https://www.ad-hoc-news.de/boerse/news/corporate-news/prothena-stock-falls-2-11-percent-as-development-chief-exits/70223595
Prothena stock experienced a 2.11% drop after its Chief Development Officer announced his departure to join a strategic partner, creating a direct link to one of Prothena's partnered development programs. Despite beating Q2 revenue consensus, the company continues to face losses, typical for a clinical-stage biotechnology firm. Analysts, however, maintain a "Moderate Buy" consensus with a significantly higher average 12-month price target.

Trading the Move, Not the Narrative: (PRTA) Edition

https://news.stocktradersdaily.com/news_release/11/Trading_the_Move,_Not_the_Narrative:_PRTA_Edition_100326121001_1791043801.html
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, identifying a mid-channel oscillation pattern and a favorable 53.5:1 risk-reward setup. It outlines specific institutional trading strategies for long and short positions, along with a multi-timeframe signal analysis, noting a prevailing neutral sentiment in shorter horizons.

A development chief is leaving Prothena (PRTA) to join one of its strategic partners.

https://www.stocktitan.net/sec-filings/PRTA/8-k-prothena-corp-public-ltd-co-reports-material-event-578943b3f1ca.html
Chad J. Swanson, Ph.D., Prothena Corporation's Chief Development Officer, is resigning effective October 9, 2026. He will be taking a leadership role at one of Prothena's strategic partners, specifically overseeing a program partnered with Prothena. This information was reported in an 8-K filing, indicating a high impact material event for the company.

Form 4 PROTHENA CORP PUBLIC LTD CO For: 1 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-1-october-93CH-2716999
This article reports on the filing of Form 4 for Prothena Corp Public Ltd Co, dated October 1. The Form 4 filing is a mandatory SEC document used to report changes in beneficial ownership of a company's stock by insiders. The article indicates that this is a routine financial filing.

Form 4 PROTHENA CORP PUBLIC LTD CO For: 29 September By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-29-september-93CH-4888576
This article announces the filing of Form 4 for PROTHENA CORP PUBLIC LTD CO, related to transactions on September 29th. It is a brief, standard disclosure from Investing.com, likely concerning insider trading activity for the company. The core content is the notification of this financial filing.
Advertisement

Prothena Corp Public Ltd Insider Bought Shares Worth $889,872, According to a Recent SEC Filing

https://finance.yahoo.com/markets/stocks/articles/prothena-corp-public-ltd-insider-214234792.html
Prothena Corp Public Ltd insider William P Scully, a 10% owner, purchased 103,500 shares of the company on September 28, 2026. This transaction is detailed in a recent SEC filing. The article indicates that a premium subscription is required to read the full details of this MT Newswires report.

Prothena Corporation stock reports a narrower Q2 loss

https://www.ad-hoc-news.de/boerse/news/nebenwerte/prothena-corporation-stock-reports-a-narrower-q2-loss/70195708
Prothena Corporation (PRTA) reported a narrower-than-expected Q2 loss of USD 0.32 per share, beating the consensus estimate of USD 0.39, and Q2 revenue of USD 1.01 million, exceeding the USD 0.42 million consensus. Despite a negative net margin, analysts maintain a "Moderate Buy" consensus with an average 12-month price target of USD 24.57, significantly above the current share price of USD 8.29. The company's pipeline of therapies for neurodegenerative diseases remains a key driver for future stock performance.

Form 4 PROTHENA CORP PUBLIC LTD CO For: 27 September By Investing.com

https://au.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-27-september-93CH-4660516
This article reports on a Form 4 filing for Prothena Corp Public Ltd Co (PRTA) for September 27. It includes the stock's performance (+5.19%) and contextualizes it within broader market news and data. The content is primarily a brief announcement, directing readers to related market information.

Form 4 PROTHENA CORP PUBLIC LTD CO For: 27 September By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-27-september-93CH-2711011
This article announces the filing of a Form 4 for Prothena Corp Public Ltd Co on September 27. Form 4 filings typically disclose changes in beneficial ownership of securities by company insiders. The brief news item indicates this financial reporting event for the company.

Form 4 PROTHENA CORP PUBLIC LTD CO For: 27 September By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-prothena-corp-public-ltd-co-for-27-september-93CH-4884503
This article reports on a Form 4 filing for PROTHENA CORP PUBLIC LTD CO (PRTA) for September 27th, 2026. The stock symbol PRTA is noted with a 4.46% increase. The article itself is very brief, serving primarily as a notice of the regulatory filing.
Advertisement

Prothena stock falls to USD 8.51 as earnings beat estimates

https://www.ad-hoc-news.de/boerse/news/nebenwerte/prothena-stock-falls-to-usd-8-51-as-earnings-beat-estimates/70154330
Prothena (PRTA) stock closed at USD 8.51 on September 21, 2026, marking a slight decline, despite the company reporting a quarterly loss of USD 0.32 per share, which was USD 0.07 better than analyst estimates. The biotechnology company's revenue of USD 1.01 million also surpassed estimates. Analysts maintain a "Moderate Buy" rating with a consensus price target of USD 24.57, significantly above the current trading price.

Prothena Corp Public Ltd Insider Bought Shares Worth $843,460, According to a Recent SEC Filing

https://finance.yahoo.com/markets/stocks/articles/prothena-corp-public-ltd-insider-202826701.html
William P Scully, a 10% owner of Prothena Corp Public Ltd, purchased 100,000 shares of the company's stock on September 18, 2026. This transaction was valued at $843,460, according to a recent SEC filing. The article highlights this insider buying activity.

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

https://investingnews.com/prothena-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference/
Prothena Corporation plc (NASDAQ: PRTA), a clinical biotechnology company, announced that its senior management team will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled for Wednesday, September 16, 2026, at 8:30 a.m. ET in New York, NY. A live webcast and replay will be available through the investor relations section of the Company's website.

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

https://finance.yahoo.com/healthcare/articles/prothena-participate-h-c-wainwright-200500949.html
Prothena Corporation plc announced that its senior management team will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. The event will be held in New York, NY, and a live webcast will be available on the company's investor relations website, with a replay accessible for 90 days afterward. Prothena is a late-stage clinical biotechnology company focusing on neurodegenerative and rare peripheral amyloid diseases.

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

https://www.biospace.com/press-releases/prothena-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference
Prothena Corporation plc (NASDAQ:PRTA) will participate in the H.C. Wainwright 28th Annual Global Investment Conference with a fireside chat on Wednesday, September 16, 2026, at 8:30 a.m. ET. A live webcast and replay will be available on the company's investor relations website. Prothena is a late-stage clinical biotechnology company focused on neurodegenerative and rare peripheral amyloid diseases.
Advertisement

Responsive Playbooks and the PRTA Inflection

https://news.stocktradersdaily.com/news_release/139/Responsive_Playbooks_and_the_PRTA_Inflection_090226104002_1788360002.html
This article from Stock Traders Daily discusses Prothena Corporation Plc (NASDAQ: PRTA), highlighting a neutral near-term sentiment while a mid-term strong sentiment may be stalling. It identifies a significant 43.0:1 risk-reward setup, targeting a 14.0% gain versus a 0.3% risk. The analysis also provides institutional trading strategies for PRTA, including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis.

Prothena Corporation plc (PRTA) Financials – Balance Sheet, Profit & Loss, Cash Flow

https://www.valueresearchonline.com/stocks/297900/prothena-corporation-plc-prta/company-financial/
This article provides a detailed financial overview of Prothena Corporation plc (PRTA), including its balance sheet, profit & loss, and cash flow data. It presents various financial ratios such as profitability, growth, valuation, solvency, and operating efficiency for the company over several years, along with its current stock performance. The data helps investors analyze Prothena's financial health and historical trends.

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

https://www.tradingview.com/news/zacks:3a2d99496094b:0-prta-s-q2-loss-narrower-than-expected-pipeline-progress-in-focus/
Prothena Corporation (PRTA) reported a narrower-than-expected adjusted loss per share of 32 cents for Q2 2026, beating the Zacks Consensus Estimate of 39 cents. Revenues matched estimates at $1.01 million. The company reaffirmed its 2026 financial guidance and provided updates on its partnered pipeline, including advancements in treatments for Parkinson's disease, ATTR amyloidosis, and Alzheimer's Disease, with potential milestone payments expected.

Prothena (NASDAQ:PRTA) Major Shareholder Buys 50,000 Shares of Stock

https://www.marketbeat.com/instant-alerts/prothena-nasdaqprta-major-shareholder-buys-50000-shares-of-stock-2026-08-21/
Prothena (NASDAQ:PRTA) major shareholder William Scully recently purchased 50,000 shares of the company's stock for $439,500, increasing his total holdings to 800,000 shares. This transaction comes as Prothena's stock rose to $9.44 and the company reported better-than-expected quarterly earnings with an adjusted loss of $0.32 per share. Analysts generally maintain a "Moderate Buy" rating for Prothena, with an average price target of $23.75.

Prothena (NASDAQ:PRTA) Shares Pass Below Two Hundred Day Moving Average - Should You Sell?

https://www.marketbeat.com/instant-alerts/prothena-nasdaqprta-shares-pass-below-two-hundred-day-moving-average-should-you-sell-2026-08-19/
Prothena (NASDAQ:PRTA) shares have fallen below their 200-day moving average, trading at $8.71 against the $9.37 average. Despite this, analysts maintain a "Moderate Buy" consensus with a $23.75 target price, and the company recently beat EPS and revenue expectations. Insider activity over the past 90 days shows net buying.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement